Statements and Responses
Read our submitted letters to editors and responses to Amgen news.
-
07.12.2024
Amgen Statement on IRS Notice Related to Horizon Acquisition -
04.29.2024
Amgen Update on Patent Litigation Related to Sandoz Denosumab Biosimilar Products -
03.01.2024
Update on Change Healthcare Cyberattack -
11.16.2023
LUMAKRAS® (sotorasib) Dose Comparison Study Results -
10.05.2023
Amgen Statement on FDA ODAC Meeting -
01.06.2023
Statement on FOURIER Analysis Published in BMJ Open -
08.16.2022
Statement on Drug Pricing Provisions Included in “Inflation Reduction Act” -
06.01.2022
Amgen Statement on Russia/Ukraine -
07.12.2021
Amgen Supports Industry Efforts to Address Global Access to COVID-19 Vaccines -
11.17.2020
Amgen Proudly Supports PhRMA’s New Principles on Clinical Trial Diversity -
07.20.2020
Oklahoma Health Care Authority and Amgen Enter into Value-Based Contract for Enbrel® (etanercept) -
05.07.2020
Amgen Comments On the Supreme Court of Japan Ruling On PCSK9 Patent Infringement Litigation -
10.18.2019
Amgen Comments on ICER’s Proposed Changes to the 2020 Value Assessment Framework -
09.09.2019
Amgen Comments on ICER’s Proposed Methods Adaptations For Assessments of Potential Cures and Other Transformative Therapies -
09.04.2019
Amgen Response in Support of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias -
07.11.2019
Amgen Comments on PCSK9 Patent Litigation in Germany -
06.17.2019
Amgen Comments for ICER’s 2020 Value Assessment Framework -
06.14.2019
Helping Patients Understand the Price of Their Medicines -
05.02.2019
Amgen Reaches Settlement With Coherus in Trade Secrets Case Regarding Pegfilgrastim -
04.25.2019
Amgen Reaches Settlement Agreement To Resolve Allegations Related To Patient Assistance Programs -
02.21.2019
Amgen’s Comments on ICER’s Value-Based Price Of A Cure Collaborative: Methodological Considerations -
02.13.2019
Amgen’s Comments on ICER’s Price Increase Draft Protocol